DEADLINE ALERT for RVNC, REGN, and BIOA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 10 2025
0mins
Source: Globenewswire
Class Action Lawsuits Announced: The Law Offices of Frank R. Cruz are representing shareholders in class action lawsuits against Revance Therapeutics, Regeneron Pharmaceuticals, and BioAge Labs, alleging misleading statements and undisclosed adverse facts about their business operations.
Investor Participation Information: Shareholders who suffered losses during the specified class periods for each company are encouraged to contact the law firm for more information on participating in these class actions before the lead plaintiff deadlines.
Analyst Views on BIOA
Wall Street analysts forecast BIOA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIOA is 13.50 USD with a low forecast of 12.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 21.510
Low
12.00
Averages
13.50
High
15.00
Current: 21.510
Low
12.00
Averages
13.50
High
15.00
About BIOA
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
